Bial - Portela C
Pre-Approval PRO BETAStale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 11/29/2021
Pipeline by Phase
Therapeutic Focus
Clinical Trials (75)
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Started: 5/31/2021
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
Started: 12/2/2008
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
Started: 3/1/2016
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
Started: 4/1/2010
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
Started: 12/1/2010
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Started: 3/1/2011
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Started: 3/1/2011
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
Started: 11/1/2010
Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia
Started: 9/1/2010
Anti-epileptogenic Effects of Eslicarbazepine Acetate
Started: 5/29/2019
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
Started: 6/3/2019
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients
Started: 2/1/2010
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
Started: 4/1/2009
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
Started: 8/1/2010
Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours
Started: 12/1/2012
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
Started: 4/1/2009
Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine
Started: 4/1/2009
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
Started: 6/11/2018
Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Started: 3/1/2014
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
Started: 2/23/2018
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
Started: 3/22/2018
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
Started: 3/31/2017
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
Started: 2/6/2018
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
Started: 10/12/2015
Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058
Started: 1/22/2019
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
Started: 5/28/2018
Relative Bioavailability and Bioequivalence of Opicapone
Started: 3/19/2019
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
Started: 2/28/2018
Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
Started: 2/20/2018
Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
Started: 6/20/2017
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067
Started: 1/27/2017
Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
Started: 12/3/2016
Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453
Started: 7/15/2008
Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites
Started: 9/1/2008
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
Started: 9/1/2011
Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
Started: 5/1/2011
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
Started: 3/1/2011
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
Started: 4/1/2008
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Started: 2/1/2010
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
Started: 3/1/2009
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Started: 6/1/2009
Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers
Started: 3/1/2014
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started: 3/1/2009
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
Started: 1/1/2009
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Started: 2/1/2014
Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
Started: 2/1/2014
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
Started: 3/1/2011
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
Started: 11/1/2009
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
Started: 6/1/2009
Effect of Rasagiline on BIA 9-1067 Pharmacokinetics
Started: 11/1/2009
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
Started: 11/1/2009
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
Started: 9/1/2008
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
Started: 10/1/2008
Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
Started: 3/1/2010
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
Started: 9/1/2008
Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
Started: 10/1/2008
Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects
Started: 6/1/2009
Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Started: 10/1/2010
Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Started: 5/1/2009
Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
Started: 5/1/2008
Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
Started: 7/1/2009
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
Started: 11/1/2008
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
Started: 9/1/2008
Effect of Opicapone at Steady State on Warfarin Pharmacokinetics
Started: 3/1/2014
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
Started: 5/1/2010
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
Started: 11/29/2021
Efficacy and Safety of Opicapone in Clinical Practice
Started: 11/23/2016